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ABSTRACT: Low ovarian reserve is a serious condition, leading to sterility in up to 10% of women in their mid-
thirties. According to current knowledge, serum anti-Müllerian hormone (AMH) levels for age are the best 
available marker for the screening the quantity of a woman’s functional ovarian reserve, better than age alone 
or other reproductive markers. This review summarizes recent findings, clinical utility and limitations in the 
application of serum AMH testing as an accurate marker for the screening of functional ovarian reserves and 
predicting age at menopause. AMH assessment hold promise in helping women make informed decisions about 
their future fertility and desired family size. However, screening of the functional ovarian reserve could be offered 
to all women at 26 years of age or older who seek to assess future fertility or in case of personal request, ovarian 
reserve screening may be considered beyond 30 years; however, it has never been advocated beyond 35 years, 
since it is not advisable to delay childbearing beyond this age. In this respect, an age-specific serum AMH levels 
lower than the 10th percentile may be used as a threshold for the identification of a low functional ovarian reserve 
in an individual woman. Its level should be interpreted with caution in the adolescent and young women aged 
below 25 years (since AMH levels peak at this age); recent users of hormonal contraceptives (since AMH levels 
transiently decrease until two months after discontinuation); and women with PCOS (which dramatically 
increases AMH levels). However, the ability of AMH levels to predict the time to menopause is promising but 
requires further investigation and routine AMH testing for the purposes of predicting the time to menopause is 
not recommended.  
 





Societal shifts triggered by a greater focus on education 
and career opportunities, developments in assisted 
reproduction, rise of effective contraception, value 
changes, gender equity, partnership changes, lack of 
suitable partners, housing conditions, economic 
uncertainty, and the absence of supportive family policies 
have resulted in a trend toward delayed childbearing 
worldwide [1]. It has been estimated that over 5% of 
pregnancies in Western countries have been occurred after 
the fourth decade of life, which the rate has been more 
than doubled in recent decades [2, 3].  
Assessment of functional ovarian reserves hold 
promise in helping women make informed decisions 
about their future fertility and desired family size, rather 
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than simply providing them with generic age-related 
fertility recommendations [4-6].  
Here, we discuss the clinical utility and limitations of 
anti-Müllerian hormone (AMH) testing as an accurate 
marker for the screening of functional ovarian reserves 
and predicting age at menopause.  
 
The functional ovarian reserve 
 
The functional ovarian reserve defines the quantity and 
quality of the ovarian primordial follicular pool, which 
declines with age in women, with a more rapid decline 
after the mid-30s until it reaches undetectable levels at 
menopause [7]. Although age is known to be the most 
important factor affecting the quality of the ovarian 
reserve, [8, 9] other intrinsic and extrinsic factors also 
play a role (Table 1) [10-21]. Therefore, women of the 
same age can vary in their fertility potential.   
 
Table 1. Factor associated with ovarian reserve. 
 
Factors Level of 
evidence 
Intrinsic factors 
 Genetic   
  Individual variation 2a 
  BRCA carrier, 2b 
  FMR1 premutation 2c 
  Fragile X 3a 
  Turner syndrome 3a 
 Race and Ethnicity 2c 
 Age 2a 
 Family history of POI or early menopause 2a 
Extrinsic factors 
 Unhealthy lifestyle factors  
  Heavy and current smoking 3b 
  Frequent binge drinking 3b 
  Vitamin D deficiency 2b 
  Body mass index (obesity) 3a 
 Medications  
  Immunosuppressive 3b 
  Chemotherapy drugs 2b 
 Ovarian Pelvic surgery 2b 
 Acute or chronic psychosocial stress 3b 
 Some Systemic or Autoimmune Disorders  3b 
 
BRCA-1, breast cancer gene-1; FMR1, POI, Premature Ovarian 
insufficiency; 2a, Systematic reviews (with homogeneity) of cohort 
studies; 2b, Individual cohort study or low quality randomized controlled 
trials; 2c, "Outcomes" Research; ecological studies; 3a, Systematic 
review (with homogeneity) of case-control studies; 3b, Individual case-
control study. 
 
Low ovarian reserve is a serious condition, leading to 
sterility in up to 10% of women in their mid-thirties, and 
is mostly irreversible [22]. The condition is often 
clinically asymptomatic, making it difficult to diagnose 
until fertility is diminished, and therefore, ovarian reserve 
screening could be offered to all women ≥26 years old 
who seek to assess future fertility [22]. However, since the 
woman's fertility start declining in their thirties, it is not 
recommended to postpone fertility after those ages, 
particularly for women who have never conceived before 
which have a lower probability of achieving a pregnancy 
in later life. However, in case of personal request, ovarian 
reserve screening may be considered beyond 30 years; 
however, it has never been advocated beyond 35 years, 
since it is not advisable to delay childbearing beyond this 
age [22]. 
Early diagnosis is critical to help women make 
informed decisions about their plans for natural 
conception, opt for oocyte vitrification, or use donated 
sperm if single, while these alternatives still have 
reasonable prospects of success [8]. Although no marker 
exists that directly measures the ovarian reserve, the size 
of the growing follicle pool remaining in the ovary is 
precisely detectable by some biomarkers, and this 
measure is referred to as the ‘functional ovarian reserve’ 
[8, 23, 24]. 
Over the years, numerous parameters have been 
proposed to estimate the functional ovarian reserve. 
Serum follicle-stimulating hormone (FSH) and antral 
follicle count (AFC) have been widely applied in 
reproductive medicine for years. Beyond their general 
predictive value, both have specific disadvantages. FSH 
levels fluctuate during the inter/intra cycle of 
menstruation; tend to increase after 35 years of age; are 
dependent on the functional hypothalamic-pituitary-
ovarian (HPO) axis; and have low sensitivity when the 
number of follicles significantly decreases. AFC has 
various sensitivities owing to technical limitations such as 
interobserver variability and ultrasound machines, which 
are restricted to antral follicles of measurable size; has 
different methodologies for counting antral follicles and 
intercycle variation in obese women; and may not be 
feasible for virgin girls in some cultures, if using the 
vaginal approach. Compared to these other parameters, 
serum AMH is currently the best proxy for assessing the 
‘functional ovarian reserve’, which supports normal 
follicle progression and ovulation [9-13]. 
 
What is Anti-Müllerian hormone? 
 
Anti-Müllerian hormone is specifically expressed by 
small growing follicles in the ovary and has an inhibitory 
effect on primordial follicular recruitment and FSH-
induced preantral follicle growth (Fig. 1) [25]. From birth 
onwards, AMH levels increase steadily till 9 years of age, 
decline slightly during the pubertal ages, and peak at 
around 25 years of age. This is followed by a gradual 
decline brought about by the reduction of the primordial 
follicle pool with age and until it reaches undetectable 
levels at an average of 50–51 years of age, corresponding 
to menopause [26]. In addition, AMH has several other 
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unique characteristics that, taken together, make it a 
reliable marker for the assessment of the functional 
ovarian reserve and time to menopause, better than age 
alone or other reproductive hormones. The important 
characteristics are that it is secreted exclusively by 
ovarian follicles at approximately constant levels from 
one cycle to another, with a consistent pattern throughout 
each menstrual cycle, particularly after the age of 30 
years. Therefore, measurements can be taken at any stage 
of the menstrual cycle. It also produces a reliable estimate 
with a single measurement and is largely independent of 
hypothalamic pituitary function. Further, the test is the 
least expensive and intrusive of the options available and 
also has the least inter-observer variability [26, 27].  
Its utility is further extended as a marker of ovarian 
responsiveness in assisted reproduction, ovulatory 
disorders such as polycystic ovary syndrome (PCOS), 
before or after ovarian damage by surgery, chemotherapy, 
or radiotherapy, as well as prediction and diagnosis of 
early menopause and premature ovarian insufficiency. In 
addition, given the specific site of production of AMH, its 
measurement has been used as a very precise marker of 
tumours originating from granulosa cells in female and 
Sertoli cells of the testis in males [28]. Moreover, it may 
be a good candidate marker for obtaining information on 
testicular function and spermatogenesis in disorders 
related to male fertility [29]. 
 
Figure 1. Schematic model of AMH production and its role in the ovary. 
What is the role of AMH in the assessment of low 
functional ovarian reserves? 
 
According to current knowledge, age-specific serum 
AMH levels, which are measured by Automated and 
therefore more accurate AMH assays [30], are the best 
available marker for the assessment of the functional 
ovarian reserves, better than age alone or other 
reproductive markers [8]. However, for clinical 
interpretation, the prediction of age at menopause (as the 
most important indicator for ovarian aging), that been 
presented according to various ages and AMH percentiles, 
can be used [31-32]. For instance, an age-specific AMH 
level lower than the 10th percentile may be used as a 
threshold for the identification of those with low 
functional ovarian reserve [22]. For example, a 30-yr-old 
woman with an AMH value less than 0.5 ng/ml has 
diminished functional reserve and is at risk of early 
menopause [31,32]. These specific values should be 
confirmed with further comprehensive studies.   
• In cases of diminished functional ovarian reserves, 
individual risk assessment should be performed 
based on repeat confirmatory AMH testing, day 3-5 
FSH measurement, and ultrasound findings of AFC. 
Final diagnosis should be made after complete 
evaluation of all results, in the context of any known 
individual risk factors for low ovarian reserves [22]. 
Women with low ovarian reserves who are 
interested in childbearing should be encouraged to 
become pregnant spontaneously within the next 6 
months. If natural conception does not occur within 
that time, assisted reproduction should be 
considered. However, since fertility is associate with 
numerous factors, the ability of AMH to predict the 
chance of pregnancy is less promising, and AMH 
should not be used as a fertility test.  
• In women with borderline diminished functional 
ovarian reserves, annual follow-up ovarian reserve 
testing is recommended. In addition, the restriction 
of factors that can increase the rate of decline, 
including impacts of certain lifestyles such as 
alcohol abuse, smoking, malnutrition, obesity, and 
stress should be highlighted. 
• In women with acceptable AMH levels, it should be 
emphasised that advanced maternal age is related to 
low quality of oocytes and is therefore strongly 
associated with an increased risk of aneuploidy and 
other adverse feto-maternal or neonatal outcomes.  
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It is important to remember that individual conditions 
can affect AMH values, and these should be considered 
prior to their clinical application and interpretation. Serum 
AMH levels do not peak until approximately 25 years of 
age; hence, care must be taken when interpreting AMH 
levels in adolescents and young women. In addition, 
hormonal contraceptive usage, particularly in long-term 
users, could transiently decrease serum concentrations of 
AMH by 20-30% but tend to recover after two months of 
discontinuation. Therefore, AMH should be measured at 
least 2 months after the discontinuation of hormonal 
contraceptives. Moreover, due to an increase in the 
number of pre-antral and small antral follicles, which 
primarily produce AMH, the serum concentration of 
AMH tends to be higher in women with PCOS compared 
to non-PCOS counterparts. Although this needs to be 
precisely defined, [33] the threshold levels for the 
prediction of PCOS in the age categories of 20–27, 27–
35, and 35–40 years could be 5.7 (95 % CI: 5.48–6.19), 
4.55 (95 % CI: 4.52–4.64), and 3.72 (95 % CI: 3.55–3.80), 
respectively, which all have positive predictive values 
(PPV) of more than 90% and negative predictive values 
of more than 80% [23-26, 34].  
Finally, women must be empowered to make 
voluntary and informed choices about whether to get 
tested based on objective information about all aspects of 
this test. Healthcare professionals may tend to focus on 
the implications of poor results, but the information 
provided should also include full aspects of both poor or 
acceptable test results and subsequent steps of action prior 
to the test is ordered.  
 
What is the role of AMH in predicting the age at 
menopause? 
 
Age-specific AMH levels may provide a fairly reasonable 
prediction of age at menopause (natural or iatrogenic), 
particularly for women who are younger than 40 years, 
even if they still have regular menstrual cycles and normal 
levels of other reproductive hormones [9, 22]. It could 
therefore provide increasing clinical value to young 
women who are at risk of early menopause due to genetic, 
familial, and environmental factors or medical 
intervention [25, 33] in cancer survivors both before and 
after gonadotoxic treatment [15]. 
Mathematical modelling has already been used to 
predict age at menopause. For example, a 30-year-old 
woman with an AMH level close to 1.1 ng/mL (7.85 
pmol/L) is known to have a predicted mean age at 
menopause of 45 (range, 37–50) years [31]; a serum level 
of AMH less than 0.1 ng/mL (0.71 pmol/L) in any 
reproductive age was strongly associated with the 
imminent onset of menopause [31-39]. Women at risk 
should be managed by proper counselling about future 
fertility and other early or late menopause-related 
problems such as cardiovascular disease, osteoporosis, 
and breast and endometrial cancers [40].  
However, based on available studies (Table 2) as well 
as available meta-analysis [41], the precise predictive 
value of serum age-specific AMH levels for time to 
menopause, remains controversial, since the majority of 
available studies have assessed regularly cycling women 
of various ethnicities, age ranges, duration of follow-up, 
and AMH assays. Moreover, the trajectory of the decline 
also seems to differ among women [42]. More 
controversies are observed when ‘extreme ages at 
menopause’, including early menopause [41] and 
premature ovarian insufficiency (POI), are predicted by 
AMH levels, and for such women, the accuracy of this 
prediction is more critical. Poor accuracy is mainly due to 
low sample sizes of women extreme ages at menopause in 
available cohorts, and by adding ongoing cohorts, the 
reliability of statistical models for prediction of POI 
should be improved [43]. At the current time, the clinical 
application of AMH levels for the prediction and 
diagnosis of menopause, particularly early menopause or 
POI, is promising but needs further investigations.   
 
Table 2. Summary of some important studies used AMH for prediction of menopause. 
 
Author Country Type of study Participants 
characteristics 











Assay kit Findings 
Bertone-
Johnson et 





Health Study II)  
Cases: N = 327, 
Age: 40.2 (2.8), 
BMI: 25.3 (0.3) 
Matched 
Controls: n = 
327, Age: 40.2 
(2.8), BMI: 
25.0 (0.3) 
- 12 years Pico 
AMH 
Each 0.10 ng/mL (0.71 
pmol/L) decrease in AMH 
was associated with a 14% 
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Broer et al. 
2011 (47)  
Netherlands Follow-up study 
at an academic 
hospital 
N = 257, Age: 
35.5 (5.9), 
BMI: 24.0 (4.0)  
48 (18.7%) 11 years DSL and 
 Gen-II 
ELISA 
AMH is capable of 
predicting future age at 
menopause for a given 
woman 
de Kat et al. 





N = 3133, Age: 




20 years picoAMH  There is no fixed pattern for 
decline rate of AMH and the 
difference between women 
with high and low age-
specific AMH levels 
decrease as age progresses. 
 
de Kat et al. 





N = 2434, Age: 
36.1 (8.1), 
BMI: - 
1298 (53%) 11.6 years picoAMH  Knowledge of the AMH 
decline rate does not improve 
the prediction of menopause 
and early menopause. 
Depmann et 





N = 216, Age: -, 
BMI: - 
81 (37.5%) 14.8 years DSL and 
Gen-II 
ELISA  
AMH alone predicts age at 
menopause; however, its 
predictive value decreased 
with increasing age of the 
woman 
Dólleman et 







N = 1163, Age: 
40.8 (7), BMI: 
23.8 (3.9) 
- 10 years Gen-II 
ELISA  
AMH has additive predictive 
value for prediction of age at 
menopause even when taking 
age, BMI, cycle regularity 
and smoking into account. 
Finkelstein 







N = 1537, Age: 
47.5 (2.6), 
BMI: 23.8 (3.9) 






picoAMH  Using an ultrasensitive 
ELISA with a limit of 
detection of 1.85 pg/ml, is 
clinically useful for 
predictions of the time to 
menopause.  
Freeman et 





N = 293, Age *: 
40.93 (40.6 –
41.3), BMI: - 




The AMH decline rate of 
change increases the 
precisions of the estimation 
of time to menopause, when 
included with an AMH 
baseline level and age, in late 
reproductive-age women.  
 
Freeman et 





N = 401, Age *: 
41.47 (41.13– 
41.82), BMI *: 
29.33 (28.56 –
30.10) 
198 (49.4%) 14-year Gen-II 
ELISA  
Among women with a 
baseline AMH level below 
0.20 ng/mL (1.42 pmol/L), 
the median time to 
menopause was 5.99 y, in the 
45- to 48-yr age group and 
9.94 y in the 35- to 39-y age 
group.  
Gohari et 










63 (23.7%) 6.5 years DSL Decline rate of AMH is 
specific for each woman and 
could predict age at 
menopause. 
Kim et al. 
2017 (9)  











55 (13%) 5 years Pico 
AMH  
The majority of women aged 
45-49 with AMH values 
<0.02 ng/dl underwent 
menopause within 5 years.   
La Marca 




N = 375, Age: 
35.3 (0.2), 
BMI: 23.2 (4.2) 
- - Gen-II 
ELISA  
There were the good level of 
conformity between the 
distributions of observed and 
AMH-predicted ages at 
menopause. Using BMI and 
smoking status as additional 
variables improves AMH 
based prediction of age at 
menopause. 
Nair et al. 
2015 (56)  
USA Population based 
cohort study 
N = 716, Age: 
42, BMI: 27.8 
207 (29%) 9 years Pico 
AMH 
AMH appears identified 
women at risk of menopause 
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in the near future, within 3 
years of AMH measurement. 
The risk of menopause was 
over 6-fold higher for a 0.5 
ng/dL (3.57 pmol/L) 
decrement in AMH.  
Ramezani 
Tehrani et 






N = 147, Age: 
44.8 (2.6), 
BMI: 28.9 (4.6) 
60 (40.8%) 6 years DSL Single AMH measurement is 
a good predictor for the onset 
of menopause. Of every 10 
women who are naturally 
fertile, aged 40 to 50 years 
with a normal menstrual 
cycle at the time of the test, 
will not reach menopause 
status within the next 6 years 
if the AMH level is greater 










N = 959, Age: 
36 (7.1), BMI: 
27 (4.7) 
529 (55.2%) 14 years Gen-II 
ELISA  
Prediction of age at 
menopause could be 
improved by multiple AMH 
measurements. On average 
for the same amount of age-
specific AMH, the predicted 
age at menopause for those 
with the highest AMH 
decline rate (95th percentiles) 
was about one decade lower 










N = 266, Age: 
37.6 (9.6), 
BMI: 27.7 (5.0) 
63 (23.7%) 6 years DSL Ages at menopause for 
different levels of serum 
AMH concentration among 
women aged 20 to 49 years 
has been presented. 
Ramezani 
Tehran et 






N = 1015, Age: 
36.7 (7.5), 
BMI: 27.1 (4.7) 
277 (27.3%) 10 years Gen-II 
ELISA  
Average age at menopause 
for individual women aged 
20 to 49 years for various 
amount of AMH is presented. 
van 
Disseldorp 







into Cancer and 
Nutrition study) 
N = 144, Age: 
37.9 (5.5), 
BMI: 24.2 (3.8) 
- - DSL There was good conformity 
between the observed 
distribution of age at 
menopause and that 
predicted from declining 
AMH levels 
van Rooij et 
al. 2004 (38)  
Netherlands Prospective 
cohort study 
N = 81, Age: -, 
BMI: - 
- 4 years Pico 
AMH 
AMH, had the high 
predictive accuracy for 
occurrence of cycle 
irregularity and could 
predictor for the occurrence 
of menopausal transition 
within 3 to 5 years 
 
What techniques can be used to measure the AMH? 
 
There were different commercial enzyme-linked 
immunosorbent assay (ELISA) kits used to measure 
AMH, which is varied in antibody pairs, standard curve 
ranges, and limits of detection [44] (Table 3). Assays for 
AMH have progressed over the years, which is the major 
step forward for clinical epidemiological use. However, 
despite the current progress, universally accepted and 
standardized materials and method of assay to measure 
the serum concentrations of AMH are still lacking. 
Meanwhile, there are not conversion protocol to 
determine comparability of AMH assays available to 
facilitate the interpretation of values obtained in different 
studies. Both needs to be defined precisely for any AMH 
clinical use. However, a picoAMH assay with a lower 
detection threshold from Ansh Laboratories are most 
sensitive assay for detection of low levels of AMH [45]. 
 
What are the limitations of AMH testing? 
 
AMH has the following limitations: 
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• The age-dependent decline rate of AMH levels 
varies among women. An international guideline 
regarding age-specific AMH diagnostic thresholds 
for screening functional ovarian reserves or 
predicting age at menopause remains to be 
addressed. 
• Some endogenous and exogenous factors could 
influence serum AMH levels, which limit the 
accurate interpretation of AMH values in a clinical 
setting. 
• The predictive value of AMH for successful 
clinical pregnancy (both in natural and assisted 
reproduction) is less promising; and therefore, 
AMH levels should not be used as a fertility test.  
• AMH assessment using manual enzyme-linked 
immunosorbent assay (ELISA) has some 
limitations due to intra-assay/interassay differences 
and requires careful sample preparation and 
storage. However, automated AMH assay 
platforms have greater precision, faster turnaround 
time, greater sensitivity, and accessibility in many 
countries and should be used as a standard method 
for AMH measurement.  
 
Table 3. Commercial assays available for AMH measurement. 
 
AMH assay, year Manufacture 
company 
Detection limit Standard 
curve range 
description 
IOT, 1999 Immunotech 0.05 ng/mL 0.1–24.5 
ng/mL   
A monoclonal antibody pair were directed, one 
directed at the pro region and the other at the 
mature region. 
DSL, 2003 Diagnostic Systems 
Lab-oratories 
0.006 ng/mL 0.05–15 ng/mL    Both monoclonal antibodies were directed at 
the mature region 
Gen II generation, 
2010 
Beckman Coulter 0.16–22.5 
ng/mL   
0.08 ng/mL The DSL antibodies were used in assay, which 
was standardized to the IOT assay 
Ultrasensitive, 2012 Ansh Labs 0.083–14.2 
ng/mL 
0.023 ng/mL Monoclonal antibody pair directed against 
specific linear epitopes in the stable pro region 
and mature region of the associated form of 
human recombinant AMH 




In conclusion, considering the precise results, the ease 
of a serum-based test, independent of specific time in the 
cycle serum, independent of hypothalamic pituitary 
function and very low inter-observer variability, AMH is 
the preferred ovarian reserve marker. However, lack of 
international guideline regarding age-specific AMH 
diagnostic thresholds for screening functional ovarian 
reserves or predicting age at menopause could limit the 
proper interpretation of AMH values in a clinical setting 
and remain to be addressed in future researches.  
Ultimately, further research is needed to understand 
whether releasing/restricting various factors that could 
affect ovarian status and also the optimal approaches that 
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